Literature DB >> 2039707

The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.

M Gion1, R Mione, O Nascimben, M Valsecchi, C Gatti, A Leon, G Bruscagnin.   

Abstract

CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039707      PMCID: PMC1972400          DOI: 10.1038/bjc.1991.179

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Follow-up of breast cancer patients.

Authors:  M Kindler; G Steinhoff
Journal:  Oncology       Date:  1989       Impact factor: 2.935

2.  Evaluation of CA15/3 serum levels in breast cancer patients.

Authors:  M Gion; R Mione; R Dittadi; S Fasan; A Pallini; G Bruscagnin
Journal:  J Nucl Med Allied Sci       Date:  1986 Jan-Mar

3.  Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.

Authors:  R Colomer; A Ruibal; J Genollá; D Rubio; J M Del Campo; R Bodi; L Salvador
Journal:  Breast Cancer Res Treat       Date:  1989-03       Impact factor: 4.872

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.

Authors:  D Kufe; G Inghirami; M Abe; D Hayes; H Justi-Wheeler; J Schlom
Journal:  Hybridoma       Date:  1984

Review 6.  Breast cancer 1985. What have we learned?

Authors:  J A Urban
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

7.  Markers in breast cancer: does CEA add to the detection by CA 15.3?

Authors:  J C Delarue; H Mouriesse; F Dubois; S Friedman; F May-Levin
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

8.  Early detection of breast cancer recurrences through periodic follow-up--is it useless?

Authors:  S Ciatto; M Rosselli Del Turco; P Pacini; G Mustacchi; M Simonis; P Sismondi; G Giardina; V Belsanti; C Aristei; A M Molino
Journal:  Tumori       Date:  1985-08-31

9.  Value of CA 15:3 in the follow-up of breast cancer patients.

Authors:  D M Pons-Anicet; B P Krebs; R Mira; M Namer
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

10.  CA 15.3 as a tumour marker in breast cancer.

Authors:  P Schmidt-Rhode; K D Schulz; G Sturm; A Raab-Frick; H Prinz
Journal:  Int J Biol Markers       Date:  1987 Sep-Dec       Impact factor: 3.248

  10 in total
  9 in total

1.  Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer.

Authors:  H Iwase; S Kobayashi; Y Itoh; H Fukuoka; T Kuzushima; H Iwata; T Yamashita; A Naitoh; K Itoh; A Masaoka
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

2.  Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC).

Authors:  Dorit Di Gioia; Volker Heinemann; Dorothea Nagel; Michael Untch; Steffen Kahlert; Ingo Bauerfeind; Thomas Koehnke; Petra Stieber
Journal:  Tumour Biol       Date:  2011-05-08

3.  TPS(TM) a circulating tumor marker in breast cancer.

Authors:  R Einarsson
Journal:  Indian J Clin Biochem       Date:  1999-07

4.  Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients.

Authors:  Amir Bahrami-Ahmadi; Fariborz Makarian; Mohammad R Mortazavizadeh; Mohammad F Yazdi; Mehdi Chamani
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

5.  An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma.

Authors:  D M O'Hanlon; M J Kerin; P Kent; D Maher; H Grimes; H F Given
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

6.  Serum CEA and CA 15-3 as prognostic factors in primary breast cancer.

Authors:  F G Ebeling; P Stieber; M Untch; D Nagel; G E Konecny; U M Schmitt; A Fateh-Moghadam; D Seidel
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

7.  CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis.

Authors:  Shifu Tang; Lili Wei; Yifan Sun; Fang Zhou; Shengbo Zhu; Renqi Yang; Yiyong Huang; Hongyu Zhang; Hong Xu; Jianqing Yang
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

Review 8.  Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.

Authors:  Meng Ye; Tao Huang; Ying Ying; Jinyun Li; Ping Yang; Chao Ni; Chongchang Zhou; Si Chen
Journal:  Oncotarget       Date:  2017-02-07

9.  Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.

Authors:  M Gion; M Plebani; R Mione; C Penzo; S Meo; A Burlina
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.